Motley Fool Australia

Next Science Ltd (ASX: NXS) Share Price and News

() Chart and Price Data

(20 mins delayed)


Bid/Ask /
Avg Daily Volume
Day Movement
Day High/Low /
52 Week Range -
Year Return (Capital)
As at

Next Science Ltd (ASX: NXS) Latest News

asx shares higher

Why the Next Science share price is racing higher today

The Next Science Ltd (ASX:NXS) share price is racing higher on Friday after being granted a patent in the United States... More »

Millionaire and Wealthy man with money raining down, cheap stocks

Why the Paradigm share price is up 250% in 2019

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are up from 99 cents on New Year’s day 2019 to $3.49 today and even hit as high... More »

balance sheet

The Next Science share price is tanking on a trading update

Will Next Science turn into a 'multi bagger' for investors? It alreadsy has four anti-bacterial FDA-approved products used in surgery. More »

share price rocket

Why the Novita Healthcare share price is now up 350% in 3 days

Novita shows how penny stocks can offfer incredible gains in percentage terms. However, penny stocks are risky. More »

healthcare shares

Is Paradigm the real deal blockbuster biotech?

Paradigm is a speculative biotech business exciting investors with news over its Zilosul drug's potential to treat osteoarthritis. More »

share price higher

Why the Polynovo share price is now up 24x in 5 years

The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the... More »

bull vs bear

Paradigm reports “ground-breaking” osteoarthritis discovery: Is it the real deal?

Paradigm Biopharmaceuticals (ASX:PAR) is looking to partner with big pharma. More »

Winners Cup Trophy

Is Paradigm Biopharmaceuticals the share market’s next huge winner?

Paradigm: Buy the rumour, sell the news? More »

Why the Bionomics share price is up 40% today

Bionomics Ltd (ASX: BNO) looks very speculative. More »

Paradigm share price tanks despite positive clinical trial update

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a speccy biotech that could sink or soar. More »

Rocket soaring through the sky

Why the Mesoblast share price is going nuts today

Mesoblast limited (ASX: MSB) has signed an important partnership with Grünenthal. More »

Healthcare technology shares

Why Telix Pharmaceuticals shares are up 80% over the past year

Telix Pharmaceuticals is an oncology researcher with a renal cancer treatment at the Phase III stage. More »

Businessman paying Australian money, ASX shares

Biotech speccy Paradigm is being tipped for the big time

Paradigm (ASX: PAR) has $78 million cash on hand and a goal to commercialise osteoarthritis drugs. More »

bull vs bear

Why the Next Science share price has more than tripled in 2019

Next Science (ASX: NXS) and Paradigm (ASX: PAR) are two widely fancied speccy biotechs. More »